Will Decreased Noradrenergic Activity Normalize Information Processing in Patients With Schizophrenia?

NACompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

May 31, 2005

Primary Completion Date

December 31, 2011

Study Completion Date

December 31, 2011

Conditions
Schizophrenia
Interventions
DRUG

clonidine

Either placebo or 25 ug, 50 uG 75 ug or 150 ug of clonidine will be added to the current medication of patients with schizophrenia, who are stable on their current medication

DRUG

clonidine

0.15 mg of clonidine will be administered to 20 healthy male volunteers

Trial Locations (1)

DK-2400

Center for Neuropsychiatric Schizophrenia Research, University of Copenhagen, Psychiatric Center Glostrup, Copenhagen NV

All Listed Sponsors
collaborator

University of Copenhagen

OTHER

collaborator

Lundbeck Foundation

OTHER

collaborator

Glostrup University Hospital, Copenhagen

OTHER

lead

Birte Glenthoj

OTHER

NCT00206986 - Will Decreased Noradrenergic Activity Normalize Information Processing in Patients With Schizophrenia? | Biotech Hunter | Biotech Hunter